| 引用本文:罗 西 川.脑心通对老年患者心脑血管病的干预治疗回顾性调查[J].世界中医药,2013,8(06):. |
|
| 脑心通对老年患者心脑血管病的干预治疗回顾性调查 |
| Retrospective Survey of Naoxintong Capsule Intervention on Senile Patients with Cardiovascular and Cerebrovascular Disease |
| 投稿时间：2012-10-30 |
| DOI：10.3969/j.issn.1673-7202.2013.06.017 |
| 中文关键词: 心肌梗死 脑梗死 脑心通 老年 |
| English Keywords:Myocardial infarction Cerebral infarction Naoxintong Elderly patients |
| 基金项目: |
|
| 摘要点击次数: 1272 |
| 全文下载次数: 1242 |
| 中文摘要: |
| 目的：回顾性调查加用步长脑心通对老年人群冠心病及脑梗死患者的二级预防及康复疗效观察。方法：选择90例80岁以上已确认急性非ST段上抬心肌梗死及急性多发腔隙性脑梗死患者；冠心病占32例，脑梗死占58例（其中有24例冠心病合并脑梗死）。均给予常规治疗，在此基础上，60例初发患者从住院当天至1周开始加服脑心通1.6g，每日3次，连续服用24个月。另30例为再发病（在出院后1~12个月内不同程度再发脑梗死和或心肌梗死）后均在常规治疗下给予加服脑心通。所有患者在治疗前后均有心电图、血脂、肝肾功能、血糖、心脏超声、颈动脉超声、头颅CT、运动耐量检查（症状改善）检查及对比；再发病率、再住院率、严重致残率、死亡率进行了统计学对照。结果：坚持早期加服脑心通组心脑血管病的血脂达标水平、运动耐量、症状改善、预后及康复明显优于未加用组。并且也明显优于晚用（再发病后加服）脑心通组；再发病率、再住院率、死亡率明显低于晚用组。结论：及早加服脑心通可使老年患者心脑血管病急性期恢复加快，预后更好，能加快康复，且再发病率、再住院率、死亡率更低。 |
| English Summary: |
| To conduct retrospective investigation on Buchang Naoxintong intervention of two-graded prevention and rehabilitation in elderly patients with CHD and cerebral infarction.Methods:90 patients above 80-years old has confirmed acute non ST segment elevation acute myocardial infarction and multiple lacunar cerebral infarction. Coronary heart disease accounted for 32 cases， cerebral infarction accounted for 58 cases (including 24 cases of coronary heart disease complicated with cerebral infarction). All patients were given conventional treatment， on top of that 60 patients of primary onset added Naoxintong 1.6g from the day of admission or 1 week， 3 times a day， till 24 months. 30 recurrence cases (1~12 in the months after hospital discharge in different degree of recurrent cerebral infarction and or myocardial infarction) took the conventional therapy with naoxintong. Before and after treatment， all patients took electrocardiogram， blood lipid， liver and kidney function， blood glucose， echocardiography， carotid artery ultrasound， CT scan， movement (symptoms) examination and comparison. Morbidity， hospitalization， severe morbidity， mortality was statistically analyzed.Results:Taking Naoxintong at early disease phase is helpful to control cardiovascular lipids， increase exercise tolerance， relieve symptoms， and prognosis and rehabilitation was much better than without taking it. It’s also significantly better than late intervention (after onset of disease) in terms of morbidity， hospitalization， mortality. Conclusions: Taking Naoxintong at early disease phase allows quicker recovery from cardio-cerebro-vascular diseases， better prognosis， reduce possibility of morbidity， hospitalization and mortality. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
